

Star Cement

Result Update

Refer to important disclosures at the end of this report

In-line results; valuations attractive

- Star Cement's Q3 results were in line with our estimates. EBITDA came in at Rs940mn vs. estimated Rs929mn and EBITDA/ton at Rs1,246 vs. estimated Rs1,236 as lower realization was offset by lower opex (coal prices down Rs100-150/ton qoq).
- Sales volumes were up 15.1% yoy, driven by 12.5% growth in cement sales (0.72mt) and 2.3x rise in clinker sales (0.034mt). Blended realization fell 5.9% yoy/5.7% qoq. We believe that adjusted for higher clinker sales, cement realization was down 4.3% qoq.
- Management expects volume growth of 5-6% in the East and 7-9% in the North East (NE) region in FY20. The 2mt cement grinding unit in Siliguri, West Bengal is expected to get commissioned in Mar/Apr'20.
- Cut FY20-22E EPS by 4-9% on lower realization and higher energy cost assumptions. We prefer Star Cement due to higher profitability, return ratios, and its presence in a lucrative NE market. Maintain Buy with a revised TP of Rs120 (9x FY22E EV/EBITDA).

Lower realization and higher costs affect performance: Star Cement's Q3 performance was affected by lower realization and higher energy costs. Realization dropped 5.9% yoy/5.7% qoq as cement prices declined Rs12/bag in NE and Rs15-25/bag in other markets in Q3. We believe that cement realization fell 4.3% qoq as the company sold higher clinker. Sales volumes improved 15.1% yoy, driven by 12.5% growth in cement volume and higher clinker sales. Sales volumes rose 7.5% yoy in NE and 29.2% yoy outside NE. Energy cost was up 13.6% yoy due to the use of imported coal and drove a 5.3% yoy increase in opex/ton. Management expects the average coal cost to rise further by Rs100/ton in FY21E (after Rs150/ton increase in FY20E). Lower realization and higher opex resulted in a 22.9% yoy decline in EBITDA and 8.4pp yoy OPM contraction. EBITDA/ton was at Rs1,246 vs. Rs1,861/Rs1,067 in Q3FY19/Q2.

Cut FY20-22E EPS; valuations attractive: We prune FY20-22 EPS estimates by 4-9% due to lower realization and higher energy cost assumptions. The company's 2mt cement grinding unit in Siliguri is expected to get commissioned in Mar/Apr'20 and will help cater to South Bengal and Bihar markets. It is further contemplating to boost its clinker capacity by 2.5mt at the existing location in Meghalaya by FY23E. We prefer Star Cement due to its presence in NE, strong margin profile, and superior return ratios. NE region is a lucrative market characterized by oligopolistic nature, where just two players are controlling 50% of the total capacity. Valuations at 7.5x/6.4x FY21/22E EV/EBITDA appear attractive. We maintain Buy rating with a revised TP of Rs120, (9x FY22E EV/EBITDA vs. 9x Sep'21E EV/EBITDA earlier). Key risk could be higher coal costs and reduction in cement prices.

Please see our sector model portfolio (Emkay Alpha Portfolio): Cement & Building Materials (Page 9)

Financial Snapshot (Consolidated).

· manoiai onaponot (onoonaatoa,				
(Rs mn)	FY18	FY19	FY20E	FY21E	FY22E
Revenue	16,145	18,310	18,424	21,109	23,429
EBITDA	5,214	4,492	4,062	4,482	5,063
EBITDA Margin (%)	32.3	24.5	22.0	21.2	21.6
APAT	3,307	2,988	2,901	3,298	3,578
EPS (Rs)	7.9	7.1	6.9	7.9	8.5
EPS (% chg)	81.0	(9.6)	(2.9)	13.7	8.5
ROE (%)	25.2	18.7	15.8	16.0	15.6
P/E (x)	11.2	12.4	12.8	11.3	10.4
EV/EBITDA (x)	7.9	8.0	8.0	7.5	6.4
P/BV (x)	2.5	2.2	1.9	1.7	1.5
Source: Company, Emkay Re	esearch				



Change in Estimates	
EPS Chg FY20E/FY21E (%) (3	3.7)/(8.7%)
Target Price change (%)	(1.8)
Target Period (Months)	12
Previous Reco	BUY
Emkay vs Consensus	

EPS Estimates

FY	20E	FY21E
Emkay	6.9	7.9
Consensus	7.3	8.6
Mean Consensus TP (12M)		Rs 121
Stock Details		
Bloomberg Code	STF	RCEM IN
Face Value (Rs)		1

Bloomberg Code	STRCEMIN
Face Value (Rs)	1
Shares outstanding (mn)	412
52 Week H/L	140 / 82
M Cap (Rs bn/USD bn)	37 / 0.51
Daily Avg Volume (nos.)	2,40,350
Daily Avg Turnover (US\$ mn) 0.3

Shareholding Pattern Dec '19	
Promoters	67.1%
FIIs	0.3%
DIIs	9.0%
Public and Others	23.7%

Price Performance										
(%)	1M	3M	6M	12M						
Absolute	(2)	(8)	(10)	1						
Rel. to Niftv	(2)	(9)	(20)	(7)						

Relative price chart



Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

Sanjeev Kumar Singh

sanjeev.singh@emkayglobal.com +91 22 6612 1255


Gurpreet Kaur

gurpreet.kaur@emkayglobal.com +91 22 6612 1285

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd/its respective connected and associated corporations and affiliates are the distributors of the research report or research analyses may only be distributed to institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore


Story in Charts

Exhibit 1: Sales volumes increased 15% yoy




Source: Emkay Research, Company

Exhibit 3: Raw material cost (including traded goods & inv. adj.) rose 28.1% yoy




Source: Emkay Research, Company

Exhibit 5: OPM contracted 844bps yoy, but up 400bps qoq




Source: Emkay Research, Company

Exhibit 2: Realization declined 5.9%yoy/5.7% qoq




Source: Emkay Research, Company

Exhibit 4: Other expenses (including freight and energy cost) was flat yoy/down 8.8% qoq



Source: Emkay Research, Company

Exhibit 6: EBITDA/ton declined 33%yoy but up 16.8% qoq



Source: Emkay Research, Company

Exhibit 7: Actual vs. Estimates (Q3FY20)

(in Do man)	Astual	Actual			ariation	Communit	
(in Rs mn)	Actual	Actual Emkay Consensus Emkay Consensus Comme					
Sales	4,512	4,658	4,517	-3.1	-0.1	On lower-than-expected realization	
EBITDA	940	929	921	1.2	2.1	In line with estimates	
EBITDA margin (%)	20.8	19.9	20.4	89bps	45bps		
Adj. PAT	712	682	657	4.4	8.5	In line with estimates	

Source: Company, Emkay Research, Bloomberg

Exhibit 8: Quarterly results

Rs mn	Q3FY19	Q4FY19	Q1FY20	Q2FY20	Q3FY20	YoY (%)	QoQ (%)	YTDFY19	YTDFY20	YoY (%)
Revenue	4,164	5,344	4,609	3,825	4,512	8.3	18.0	12,966	12,945	(0.2)
Expenditure	2,945	4,076	3,487	3,181	3,572	21.3	12.3	9,743	10,240	5.1
as % of sales	71%	76%	76%	83%	79%					
Consumption of RM	671	1,374	968	907	989	47.5	9.1	2,881	2,865	(0.5)
as % of sales	16%	26%	21%	24%	22%					
Employee Expenses	300	275	298	293	324	7.9	10.4	889	916	3.0
as % of sales	7%	5%	6%	8%	7%					
Other Expenses	1,974	2,427	2,220	1,980	2,259	14.4	14.0	5,973	6,459	8.1
as % of sales	47%	45%	48%	52%	50%					
EBITDA	1,219	1,269	1,121	644	940	(22.9)	46.0	3,223	2,705	(16.1)
Depreciation	264	238	222	225	232	(12.2)	3.1	818	680	(17.0)
EBIT	955	1,030	899	418	708	(25.9)	69.2	2,405	2,025	(15.8)
Other Income	10	34	74	77	65	520.4	(15.4)	20	216	955.0
Interest	26	31	28	8	38	47.4	398.5	113	74	(34.8)
PBT	939	1,034	945	487	734	(21.8)	50.6	2,312	2,167	(6.3)
Total Tax	102	118	106	34	22	(78.4)	(35.5)	178	162	(8.9)
Adjusted PAT	837	916	839	453	712	(14.9)	57.1	2,134	2,005	(6.1)
Extra ordinary items	-	-	-	-	-			-	-	
Reported PAT	837	916	839	453	712	(14.9)	57.1	2,134	2,005	(6.1)
(Profit)/loss from JVs/Ass/MI	14	18	0	7	0	(99.4)	(98.7)	44	7	(83.1)
PAT after MI	823	898	839	446	712	(13.4)	59.6	2,090	1,997	(4.4)
Adjusted EPS	2.0	2.1	2.0	1.1	1.7	(13.4)	59.6	5.0	4.8	(4.4)
Margins (%)										
EBIDTA	29.3	23.7	24.3	16.8	20.8	(844)	400	24.9	20.9	(396)
CDIT	22.0	10.2	10 E	10.0	15.7	(724)	175	10 E	15.6	(200)

Margins (%)										
EBIDTA	29.3	23.7	24.3	16.8	20.8	(844)	400	24.9	20.9	(396)
EBIT	22.9	19.3	19.5	10.9	15.7	(724)	475	18.5	15.6	(290)
EBT	22.6	19.3	20.5	12.7	16.3	(628)	353	17.8	16.7	(109)
PAT	20.1	17.1	18.2	11.9	15.8	(431)	393	16.5	15.5	(97)
Effective Tax rate	10.9	11.4	11.2	7.0	3.0	(788)	(401)	7.7	7.5	(22)

Source: Emkay Research, Company

Exhibit 9: Operating performance on per-ton basis

Particulars	Q3FY19	Q4FY19	Q1FY20	Q2FY20	Q3FY20	YoY (%)	QoQ (%)	YTDFY19	YTDFY20	YoY (%)
Cement Volumes (mt)	0.66	0.84	0.73	0.60	0.75	15.1	25.0	2.0	2.1	3.3
Raw Material Consumed	1,024	1,639	1,332	1,505	1,312	28.1	(12.8)	1,427	1,375	(3.7)
Employee Expenses	458	328	411	487	430	(6.3)	(11.7)	441	439	(0.3)
Other Expenses	3,014	2,895	3,054	3,284	2,995	(0.6)	(8.8)	2,960	3,100	4.7
Total Cost	4,497	4,863	4,797	5,275	4,737	5.3	(10.2)	4,828	4,914	1.8
Realization	6,358	6,376	6,339	6,343	5,984	(5.9)	(5.7)	6,425	6,212	(3.3)
EBIDTA	1,861	1,513	1,542	1,067	1,246	(33.0)	16.8	1,597	1,298	(18.7)

Source: Company, Emkay Research

Emikay Research is also available on www.emikayglobal.com and Bloomberg EMKAY<GO> DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd,its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

Exhibit 10: Changes in estimates

Rs mn		FY20E			FY21E			FY22E	
13 1111	Earlier	Revised	Chg (%)	Earlier	Revised	Chg (%)	Earlier	Revised	Chg (%)
Sales vol (mt)	2.9	2.9	2.3%	3.19	3.28	2.8%	3.43	3.53	3.0%
Realization (Rs/ton)	6,390	6,283	-1.7%	6,550	6,440	-1.7%	6,747	6,633	-1.7%
Sales	18,244	18,424	1.0%	20,865	21,109	1.2%	23,156	23,429	1.2%
EBIDTA	4,175	4,062	-2.7%	4,832	4,482	-7.2%	5,440	5,063	-6.9%
EBIDTA (%)	22.9	22.0	-85	23.2	21.2	-197	23.5	21.6	-189
Net Profit	3,013	2,901	-3.7%	3,611	3,298	-8.7%	3,916	3,578	-8.6%
EPS (Rs)	7.2	6.9	-3.7%	8.6	7.9	-8.7%	9.3	8.5	-8.6%

Source: Company, Emkay Research

Exhibit 11: Key assumptions

Particulars (Rs/ton)	FY17	FY18	FY19	FY20E	FY21E	FY22E
Sales volume (mt)	2.8	2.6	2.9	2.9	3.3	3.5
Realization	5,425	6,210	6,411	6,283	6,440	6,633
Raw material	1,208	1,163	1,529	1,514	1,552	1,598
Employee cost	421	413	408	425	410	404
Other Expense	2,345	2,628	2,901	2,959	3,110	3,198
Opex	3,975	4,205	4,838	4,897	5,072	5,200
EBITDA	1,450	2,005	1,573	1,385	1,367	1,433


Source: Company, Emkay Research

Exhibit 12: Peer valuation

	Rs bn	EV/	EBITDA (x)	EV	Ton (USE	D)	I	EPS (Rs)			P/E (x)	
Company	Мсар	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E
Star Cement	37.1	8.0	7.5	6.4	79	81	84	6.9	7.9	8.5	12.8	11.3	10.4
ACC*	280.3	10.0	10.1	9.3	110	112	109	77.8	79.2	88.4	19.3	19.0	17.0
Ambuja Cements*	425.0	13.7	13.2	11.7	140	141	138	6.9	7.2	7.9	30.5	29.2	26.5
India Cements	26.6	7.4	6.5	5.8	53	52	50	4.9	7.0	10.0	15.7	11.0	7.7
Ramco Cements	190.9	17.8	16.9	15.0	155	158	152	25.5	25.5	29.5	31.1	31.1	26.9
Shree Cements	809.7	23.0	21.4	17.7	290	272	255	425.6	421.7	481.1	58.7	59.3	52.0
UltraTech Cement	1254.6	15.3	13.9	12.4	184	175	163	129.2	151.0	177.6	34.6	29.6	25.2
JK Lakshmi Cement	43.6	7.9	8.7	8.0	60	61	58	21.2	16.9	20.4	16.8	21.2	17.6
JK Cement	107.4	11.6	11.2	9.8	184	182	178	72.4	57.5	68.6	19.5	24.6	20.6
Orient Cement	17.3	8.1	7.6	6.3	51	50	48	3.9	4.3	6.5	20.7	18.4	12.3
Prism Cement	33.0	8.8	8.2	7.4	100	102	103	3.2	3.5	4.1	20.8	18.9	16.1
Sanghi Industries	10.1	11.4	8.3	7.4	35	53	53	2.9	2.7	3.2	12.7	14.0	11.5


Source: Company, Emkay Research, * December-ending companies

Exhibit 13: 1-yr forward P/E chart



Source: Company, Emkay Research

Exhibit 14: 1-yr forward EV/EBITDA chart



Source: Company, Emkay Research

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd.its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

Con-call highlights

- Volume details: Clinker production was 0.57mt vs. 0.60mt in Q3FY19. Cement production from own plants stood at 0.65mt vs. 0.59mt in Q3FY19. Cement/Clinker sales volumes stood at 0.72mt/0.034mt vs. 0.64mt/0.015mt in Q3FY19. Cement volumes in NE/outside NE markets were at 0.53mt/0.18mt vs. 0.49mt/0.14. In Q3, volumes sold outside NE grew 29% yoy. In 9MFY20, demand in NE grew 7% yoy. Star also saw volume growth of 7% in NE markets. Demand in the East region also saw a revival in Q3 and Jan-Feb'20 after a decline in Q1 and flat volumes in Q2. Star has a 24% market share in NE.
- **Demand outlook and guidance:** Demand in NE is driven by individual housing, which received a boost after the interest subvention scheme introduced by the central government. Demand from the infrastructure sector remained subdued. Management expects demand in NE/East regions to grow by 8-9%/5-6% in FY20. It expects 15-20% yoy volume growth in NE markets in FY21. EBITDA/ton should be at Rs1,500-Rs1,550 in FY20.
- Pricing trend: In Q3, prices reduced Rs12/bag in NE and Rs15-25/bag in other markets of the East region. However, in Jan/Feb'20, prices have been better than Q3 average. There has been a price increase of Rs10/bag price in NE and Rs15-18/bag in other markets of the East region after Q3.
- Capacity addition and capex: The Siliguri GU of 2mt is on schedule and will be commissioned in Mar/Apr'20. This unit will be eligible for VAT subsidies (75% exemption) under the West Bengal Industrial Policy. However, the state government has not been disbursing subsidies over the last few years. Hence, the company does not expect subsidies inflow for this plant. The Siliguri GU will cater to North Bengal and Eastern Bihar regions. Average lead distance from this plant will be approx. 400-500km. The remaining capex for this plant is Rs1bn and will be disbursed by FY20-end. The 2mt clinker unit in Meghalaya has obtained the single-window clearance; however, the environmental clearance is still pending. It also plans to set up a 15MW waste heat recovery plant (WHRS) with this clinker unit. Overall capex for the project is Rs11bn, of which Rs1.5-2bn will be spent in FY21. The plant is expected to be commissioned by FY23.
- Costs trend: Power and fuel costs per ton increased 14% yoy, while freight costs/ton declined 2% yoy. Fuel costs were higher due to higher coal consumption (85% imported coal and 15% domestic coal). The government of Meghalaya banned coal mining in July'19. This is expected to affect costs by Rs150/ton in FY20E and Rs250-300/ton in FY21E. The Supreme Court has allowed mechanical mining but mining activities have not started yet. Outstanding subsidies are only Rs500mn now, which is expected to be received in Q4.
- Blended mix: PPC: OPC: PSC sales volumes mix was maintained at 84%:14%:2% in Q3.

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<0>. DBS Bank Ltd, DBS Vickers Securities (Singapore) Ple Ltd, its respective connected and associated corporations and affiliates are the distributors of the research report or research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

Key Financials (Consolidated)

Income Statement

Y/E Mar (Rs mn)	FY18	FY19	FY20E	FY21E	FY22E
Revenue	16,145	18,310	18,424	21,109	23,429
Expenditure	10,932	13,819	14,362	16,627	18,366
EBITDA	5,214	4,492	4,062	4,482	5,063
Depreciation	1,207	1,056	1,049	1,136	1,250
EBIT	4,007	3,435	3,013	3,347	3,812
Other Income	44	55	301	361	203
Interest expenses	525	144	68	21	17
PBT	3,526	3,346	3,246	3,687	3,998
Tax	164	296	325	369	400
Extraordinary Items	0	0	0	0	0
Minority Int./Income from Assoc.	(55)	(62)	(20)	(20)	(20)
Reported Net Income	3,307	2,988	2,901	3,298	3,578
Adjusted PAT	3,307	2,988	2,901	3,298	3,578

Balance Sheet

Y/E Mar (Rs mn)	FY18	FY19	FY20E	FY21E	FY22E
Equity share capital	419	419	419	419	419
Reserves & surplus	14,344	16,817	18,976	21,287	23,878
Net worth	14,763	17,237	19,395	21,706	24,297
Minority Interest	621	683	703	723	743
Loan Funds	4,324	738	397	317	254
Net deferred tax liability	(2,329)	(2,710)	(2,710)	(2,710)	(2,710)
Total Liabilities	17,379	15,947	17,808	20,060	22,608
Net block	7,847	7,223	6,574	9,438	13,188
Investment	14	17	17	17	17
Current Assets	14,509	12,275	12,004	12,089	14,193
Cash & bank balance	198	2,113	4,817	3,855	4,936
Other Current Assets	0	0	0	0	0
Current liabilities & Provision	5,349	4,311	4,787	5,485	6,791
Net current assets	9,160	7,964	7,217	6,604	7,402
Misc. exp	0	0	0	0	0
Total Assets	17,379	15,947	17,808	20,060	22,608

Cash Flow

Y/E Mar (Rs mn)	FY18	FY19	FY20E	FY21E	FY22E
PBT (Ex-Other income) (NI+Dep)	3,526	3,346	3,246	3,687	3,998
Other Non-Cash items	527	141	89	21	17
Chg in working cap	(345)	2,245	3,451	(350)	284
Operating Cashflow	4,206	6,150	7,209	3,764	4,946
Capital expenditure	(324)	(805)	(3,657)	(4,000)	(3,000)
Free Cash Flow	3,882	5,345	3,553	(236)	1,946
Investments	26	(1,153)	0	0	0
Other Investing Cash Flow	0	0	0	0	0
Investing Cashflow	(253)	(1,911)	(3,356)	(3,639)	(2,797)
Equity Capital Raised	0	0	0	0	0
Loans Taken / (Repaid)	(3,407)	(2,816)	(342)	(79)	(63)
Dividend paid (incl tax)	0	(516)	(740)	(987)	(987)
Other Financing Cash Flow	0	0	0	0	0
Financing Cashflow	(3,929)	(3,476)	(1,150)	(1,088)	(1,067)
Net chg in cash	24	763	2,704	(962)	1,082
Opening cash position	201	198	2,113	4,817	3,855
Closing cash position	198	2,113	4,817	3,855	4,936

Source: Company, Emkay Research

Emikay Research is also available on www.emikayglobal.com and Bloomberg EMKAY<GO> DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd,its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

Key Ratios

Profitability (%)	FY18	FY19	FY20E	FY21E	FY22E
EBITDA Margin	32.3	24.5	22.0	21.2	21.6
EBIT Margin	24.8	18.8	16.4	15.9	16.3
Effective Tax Rate	4.7	8.9	10.0	10.0	10.0
Net Margin	20.8	16.7	15.9	15.7	15.4
ROCE	22.7	20.9	19.6	19.6	18.8
ROE	25.2	18.7	15.8	16.0	15.6
RoIC	23.4	23.0	27.3	31.6	27.4

Per Share Data (Rs)	FY18	FY19	FY20E	FY21E	FY22E
EPS	7.9	7.1	6.9	7.9	8.5
CEPS	10.8	9.6	9.4	10.6	11.5
BVPS	35.2	41.1	46.3	51.8	58.0
DPS	0.0	1.0	1.5	2.0	2.0

Valuations (x)	FY18	FY19	FY20E	FY21E	FY22E
PER	11.2	12.4	12.8	11.3	10.4
P/CEPS	8.2	9.2	9.4	8.4	7.7
P/BV	2.5	2.2	1.9	1.7	1.5
EV / Sales	2.6	2.0	1.8	1.6	1.4
EV / EBITDA	7.9	8.0	8.0	7.5	6.4
Dividend Yield (%)	0.0	1.1	1.7	2.3	2.3

Gearing Ratio (x)	FY18	FY19	FY20E	FY21E	FY22E
Net Debt/ Equity	0.3	(0.1)	(0.2)	(0.2)	(0.2)
Net Debt/EBIDTA	0.8	(0.3)	(1.1)	(8.0)	(0.9)
Working Cap Cycle (days)	202.6	116.6	47.5	47.5	38.4

Growth (%)	FY18	FY19	FY20E	FY21E	FY22E
Revenue	5.7	13.4	0.6	14.6	11.0
EBITDA	31.6	(13.8)	(9.6)	10.3	12.9
EBIT	44.0	(14.3)	(12.3)	11.1	13.9
PAT	81.1	(9.6)	(2.9)	13.7	8.5

Quarterly (Rs mn)	Q3FY19	Q4FY19	Q1FY20	Q2FY20	Q3FY20
Revenue	4,164	5,344	4,609	3,825	4,512
EBITDA	1,219	1,269	1,121	644	940
EBITDA Margin (%)	29.3	23.7	24.3	16.8	20.8
PAT	823	898	839	446	712
EPS (Rs)	2.0	2.1	2.0	1.1	1.7

Source: Company, Emkay Research

Shareholding Pattern (%)	Dec-18	Mar-19	Jun-19	Sep-19	Dec-19
Promoters	68.9	68.0	67.9	67.9	67.1
FIIs	1.2	1.2	1.1	0.8	0.3
DIIs	8.7	8.7	9.2	9.3	9.0
Public and Others	21.2	22.1	21.8	22.1	23.7

Source: Capitaline


Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO> DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd,its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

RECOMMENDATION HISTORY TABLE

	HON HIGHORY	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
Date	Closing Price	TP	Period (months)	Rating	Analyst
20-Nov-19	98	122	12m	Buy	Sanjeev Kumar Singh
08-Nov-19	96	122	12m	Buy	Sanjeev Kumar Singh
23-Sep-19	98	135	12m	Buy	Sanjeev Kumar Singh
26-Aug-19	93	135	12m	Buy	Sanjeev Kumar Singh
01-Aug-19	96	135	12m	Buy	Sanjeev Kumar Singh
24-Jun-19	122	153	12m	Buy	Sanjeev Kumar Singh
08-May-19	107	153	12m	Buy	Sanjeev Kumar Singh
05-Feb-19	90	150	12m	Buy	Sanjeev Kumar Singh
07-Jan-19	103	167	12m	Buy	Sanjeev Kumar Singh
13-Nov-18	100	156	12m	Buy	Sanjeev Kumar Singh
27-Jul-18	114	168	12m	Buy	Sanjeev Kumar Singh
18-May-18	128	171	12m	Buy	Sanjeev Kumar Singh
05-Apr-18	124	171	12m	Buy	Sanjeev Kumar Singh
05-Feb-18	122	170	12m	Buy	Sanjeev Kumar Singh

Source: Company, Emkay Research

RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research



Analyst: Sanjeev Kumar Singh

Contact Details

sanjeev.singh@emkayglobal.com +91 22 6612 1255

Sector

Cement & Building materials

Analyst bio

Sanjeev Kumar Singh holds an MBA and has over 10 years of experience in the Cement sector. His team currently covers 17 stocks in the Cement and Building Materials space.

Emkay Alpha Portfolio – Cement & Building Materials

EAP sector portfolio

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight (Normalised)
Cement & Building Materials	2.21	2.21	0%	0	100.00
ACC	0.20	0.21	7%	1	9.45
Ambuja Cements	0.24	0.11	-55%	-13	4.82
Grasim Industries	0.49	0.56	14%	7	25.25
India Cements	0.00	0.00	NA	0	0.00
JK Cement	0.00	0.06	NA	6	2.52
Jk Lakshmi Cement	0.00	0.00	NA	0	0.00
Orient Cement	0.00	0.00	NA	0	0.00
Prism Johnson	0.00	0.00	NA	0	0.00
Ramco Cements	0.16	0.12	-24%	-4	5.37
Sanghi Industries	0.00	0.00	NA	0	0.00
Shree Cements	0.35	0.28	-20%	-7	12.74
Star Cement	0.00	0.00	NA	0	0.00
Ultratech Cement	0.78	0.88	13%	10	39.84
Century Plyboards	0.00	0.00	NA	0	0.00
HSIL*	0.00	0.00	NA	0	0.00
Kajaria Ceramics	0.00	0.00	NA	0	0.00
Somany Ceramics	0.00	0.00	NA	0	0.00
Cash	0.00	0.00	NA	0	0.00


Source: Emkay Research

Sector portfolio NAV

	Base				
	01-Apr-19	07-Nov-19	07-Jan-20	06-Feb-20	
EAP - Cement & Building Materials	100.0	99.5	99.4	105.7	
BSE200 Neutral Weighted Portfolio (ETF)	100.0	96.4	96.2	102.4	

^{*}Performance measurement base date 1st April 2019 Source: Emkay Research

NAV chart



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): SMID

Please see our model portfolio (Emkay Alpha Portfolio): Nifty

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd,its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

^{*} Not under coverage: Equal Weight

[■] High Conviction/Strong Over Weight

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.	
BUY	Over 15%	
HOLD	Between -5% to 15%	
SELL	Below -5%	

Completed Date: 07 Feb 2020 23:47:54 (SGT) Dissemination Date: 07 Feb 2020 23:48:54 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayolobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

- This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.
- Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on the sender. Further, this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd, its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

GENERAL DISCLOSURE/DISCLAIMER BY DBS BANK LTD AS DISTRIBUTOR OF THE RESEARCH REPORT

This report is solely intended for the clients of DBS Bank Ltd,its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBS Bank Ltd.

The research set out in this report is based on information obtained from sources believed to be reliable, but we (which collectively refers to DBS Bank Ltd, its respective connected and associated corporations, affiliates and their respective directors, officers, employees and agents (collectively, the "DBS Group") have not conducted due diligence on any of the companies, verified any information or sources or taken into account any other factors which we may consider to be relevant or appropriate in preparing the research. Accordingly, we do not make any representation or warranty as to the accuracy, completeness or correctness of the research set out in this report. Opinions expressed are subject to change without notice. This research is prepared for general circulation. Any recommendation contained in this document does not have regard to the specific investment objectives, financial situation and the particular needs of any specific addressee. This document is for the information of addressees only and is not to be taken in substitution for the exercise of judgement by addressees, who should obtain separate independent legal or financial advice. The DBS Group accepts no liability whatsoever for any direct, indirect and/or consequential loss (including any claims for loss of profit) arising from any use of and/or reliance upon this document and/or further communication given in relation to this document. This document is not to be construed as an offer or a solicitation of an offer to buy or sell any securities. The DBS Group, along with its affiliates and/or persons associated with any of them may from time to time have interests in the securities mentioned in this document. The DBS Group, may have positions in, and may effect transactions in securities mentioned herein and may also perform or seek to perform broking, investment banking and other banking services for these companies. Any valuations, opinions, estimates, forecasts, ratings or risk assessments herein constitutes a judgment as of the date of this report, and there can be no assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments. The information in this document is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed, it may not contain all material information concerning the company (or companies) referred to in this report and the DBS Group is under no obligation to update the information in this report. This publication has not been reviewed or authorized by any regulatory authority in Singapore, Hong Kong or elsewhere. There is no planned schedule or frequency for updating research publication relating to any issuer.

The valuations, opinions, estimates, forecasts, ratings or risk assessments described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. It can be expected that one or more of the estimates on which the valuations, opinions, estimates, forecasts, ratings or risk assessments were based will not materialize or will vary significantly from actual results. Therefore, the inclusion of the valuations, opinions, estimates, forecasts, ratings or risk assessments described herein IS NOT TO BE RELIED UPON as a representation and/or warranty by the DBS Group (and/or any persons associated with the aforesaid entities), that: (a) such valuations, opinions, estimates, forecasts, ratings or risk assessments or their underlying assumptions will be achieved, and (b) there is any assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments stated therein. Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets. Any assumptions made in this report that refers to commodities, are for the purposes of making forecasts for the company (or companies) mentioned herein. They are not to be construed as recommendations to trade in the physical commodity or in the futures contract relating to the commodity referred to in this report.

DBSVUSA, a US-registered broker-dealer, does not have its own investment banking or research department, has not participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months and does not engage in marketmaking.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate1 does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<0>. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd, its respective connected and associated corporations and affiliates are the distributors of the research report or research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

February 7, 2020I 11

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of February 7, 2020
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of February 7, 2020.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the February 7, 2020
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the February 7, 2020

sa: sunit tirumatai February 7, 2020| 12

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY DBS BANK LTD AS DISTRIBUTOR OF THE RESEARCH REPORT

- 1. DBS Bank Ltd., DBS HK, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS") or their subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of 30 Jun 2019.
- 2. Neither DBS Bank Ltd nor DBS HK market makes in equity securities of the issuer(s) or company(ies) mentioned in this Research Report.

Compensation for investment banking services:

3. DBSVUSA, does not have its own investment banking or research department, nor has it participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months. Any US persons wishing to obtain further information, including any clarification on disclosures in this disclaimer, or to effect a transaction in any security discussed in this document should contact DBSVUSA exclusively.

Disclosure of previous investment recommendation produced:

4. DBS Bank Ltd. DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by DBS Bank Ltd. DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates in the preceding 12 months.

RESTRICTIONS ON DISTRIBUTION

General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd,its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

SINGAPORE

DBS Bank Ltd

Contact: Janice Chua

12 Marina Boulevard, Marina Bay Financial Centre Tower 3

Singapore 018982 Tel. 65-6878 8888 Fax: 65 65353 418

e-mail: equityresearch@dbs.com Company Regn. No. 196800306E

THAILAND

DBS Vickers Securities (Thailand) Co Ltd

Contact: Chanpen Sirithanarattanakul 989 Siam Piwat Tower Building,

9th, 14th-15th Floor

Rama 1 Road, Pathumwan, Nagkok Thailand 10330 Tel. 66 2 857 7831 Fax: 66 2 658 1269

e-mail: research@th.dbs.com

Company Regn. No 0105539127012

Securities and Exchange Commission, Thailand

INDONESIA

PT DBS Vickers Sekuritas (Indonesia)

Contact: Maynard Priajaya Arif

DBS Bank Tower Ciputra World 1, 32/F Jl. Prof. Dr. Satrio Kav. 3-5 Jakarta 12940, Indonesia Tel. 62 21 3003 4900

Fax: 62 21 3003 4943

e-mail: indonesiaresearch@dbs.com